About Us
A Differentiated Approach to Target and Drug Discovery
At Invea, we use a proprietary AI platform to expedite the discovery and development of precision medicines for gastrointestinal and hepatobiliary disorders impacted by dysregulation of the GBA. We have focused our attention on applying AI and machine learning as a force multiplier to aid in target and drug discovery, disease indication prioritization, through to successful clinical development and approval.
Our differentiated approach
- Delves deep into the critical components of the GBA, including inflammasomes and their activation and neuroinflammatory pathways, and
- Leverages an AI and machine learning platform to comprehensively decode the complex biological systems of the GBA to identify targets and drugs at unprecedented speed and scale and with a de-risked profile.

We were spun out by InveniAI, our parent, in 2021 and are headquartered in Guilford, Connecticut.
Meet our team
We leverage an executive team and board of directors and advisors with a track record of creating lasting impact in healthcare innovation.
Executive Management
Board of Directors
Executive Management
Board of Directors
© 2022 Invea Therapeutics, Inc. All rights reserved